✦ LIBER ✦

Validation and clinical usefulness of an objective plan evaluation model in the three-dimensional treatment of non-small cell lung cancer

✍ Scribed by Mary V. Graham; Nilesh L. Jain; Michael G. Kahn; Robert E. Drzymalal; Michael A. Mackeyl; James A. Purdyl

Publisher: Elsevier Science
Year: 1993
Tongue: English
Weight: 134 KB
Volume: 27
Category: Article
ISSN: 0360-3016
DOI: 10.1016/0360-3016(93)90812-a

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of neoadjuvant chemothera

Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer

✍ Margaret Deutsch; Jeffrey Crawford; Kenneth Leopold; Walter Wolfe; William Foste 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 939 KB

Evaluation of synergism by a novel three

Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung-cancer cell line, SBC-3

✍ Fumihiko Kanzawa; Kazuto Nishio; Kazuya Fukuoka; Minoru Fukuda; Takehiko Kunimot 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 206 KB 👁 2 views

Although the combination of cisplatin and etoposide has been used as standard therapy for small-cell lung cancer, it is difficult to demonstrate combination effects between cisplatin and etoposide in vitro. We therefore adopted a 3-dimensional (3-D) model to analyze the combination effects of antica

Phase II study of N-methylformamide, spi

Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): An Eastern cooperative oncology group study

✍ Ettinger, David S. ;Finkelstein, Dianne M. ;Donehower, Ross C. ;Chang, Alex Y. C 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 407 KB

One hundred forty-four patients with non-small cell lung cancer, the majority (72%) of whom had received previous chemotherapy, were evaluable in this randomized phase II study of N-methylformamide (N-MF), spirogermanium, and 4-demethoxydaunorubicin. There were two partial responses, one each with s